Skip to content
Home/ Young Blood: How the Plasma Transfusion Industry Built a Billion-Dollar Market on Research That Coul
Young Blood: How the Plasma Transfusion Industry Built a Billion-Dollar Market on Research That Coul
Save Ask us

Young Blood: How the Plasma Transfusion Industry Built a Billion-Dollar Market on Research That Coul

No customer reviews yet ISBN 9798198566347
Published
May 2026
Language
English
$17.62 $19.99 11% off
You save $2.37 · list price $19.99
In stock soon — order now to reserve your copy
This book can take longer to arrive. Shipping policy
Qty
Sign in to Add to Saved list
Free delivery over $35 · 15-day returns

Condition

Brand New

An unread, unused copy: no writing or highlighting, and no missing or damaged pages. Every book we sell is brand new, including our lowest-priced titles.

About this book

Young Blood By Milo Cresvik

A retired chemistry teacher hands over six thousand dollars for a treatment that has never been proven to work. She has read the Stanford research. She has printed the papers. She is intelligent, careful, and trusting a system that does not deserve her trust.

Milo Cresvik was the molecular biologist in the building.

For four years he ran the assays, attended the meetings, and read every paper until he understood precisely how wide the gap was between what the science said and what patients were being told. This is his account of how a genuinely fascinating hypothesis, that young blood contains factors which slow aging, became a billion-dollar commercial enterprise before a single controlled human trial had confirmed it worked.

The science is real. Stanford researchers discovered that old mice connected to young ones showed measurable signs of biological rejuvenation. The finding was honest, careful, and opened important questions. None of that stopped a wave of startups from turning a mouse experiment into a medical product, charging thousands per infusion, and building investor decks that cited peer-reviewed papers while omitting the replication failures and internal studies that told a far more complicated story.

Cresvik was in the room for all of it. The presentations where uncertainties were buried under Risk Factors. The meetings where uncontrolled self-report data was called consistent with preclinical findings. The conversation where a founder admitted he knew the science was not where the story was, and had decided to bet it would get there in time.

It did not get there in time.

In February 2019, the FDA issued a public warning. Programs suspended overnight. Patients who had spent tens of thousands across multiple infusions were left with receipts and the memory of being told the research was very promising.

This is not a story about villains. It is more unsettling than that. The people who built these programs were believers who applied Silicon Valley's move fast ideology to a domain where speed has always cost lives. The scientists who stayed, including Cresvik himself, made ordinary compromises until those compromises became something that deserved a harder name.

He includes himself in the accounting. He was there. He knew. This book is what he should have said sooner.

Milo Cresvik holds a doctorate in molecular biology and spent four years as a research scientist inside the plasma transfusion industry.

Specifications

PublishedMay 25, 2026
ISBN-109798198566347
ISBN-139798198566347
LanguageEnglish

Buying from Saanjhi

  • Ships from the USA. Delivery to US addresses only.
  • Free delivery on orders over $35.
  • 15-day returns. Unless we send the wrong book or it arrives damaged, you pay return shipping and a 15% restocking fee.
  • Secure checkout. We never store card details.